Ovagen
performance. 48% of patients noticed a considerable decrease in the intensity of the pain syndrome.
Cancer patients noted an improvement in their well-being, a decrease in weakness, and the intensity
of dyspeptic disorders.
Influence of OVAGEN® on Biochemical indicators of peripheral blood in Table 2
patients with chronic hepatitis.
Indicator Before After Treatment with After Treatment with Ovagen®
treatment Conventional Means
Cholesterol, (mmol/l) 4,8±0,3 4,9±0,1 4,7±0,6
Bilirubin, (mcmol/l) 28,4±0,5 26,4±1,1 21,5±0,7*
AST, (mmol/hxl) 38,6±2,1 40,2±2,2 36,1±2,5
ALT, (mmol/hxl) 50,2±3,2 44,3±3,1* 41,4±2,8*
g-GT, (mmol/hxl) 44,7±4,3 42,6±4,0 41,4±4,1
Triglycerides, (mmol/l) 2,2±0,2 2,1±0,7 1,8±0,4
* P <0.05 - reliablein comparison with the parameter before treatment.
When analyzing the effectiveness of OVAGEN®, particular attention was paid to assessing the results
of biochemical studies characterizing the liver’s aminotransferase activity, pigment, and protein-form-
ing functions. Objectively, after using OVAGEN®, biochemical parameters were stabilizing in most
patients: bilirubin level, alanine aminotransferase level (Table 2). The study of peripheral blood immu-
noglobulins, which are an essential criterion for the inflammatory process activity, after a course of
treatment using OVAGEN® showed a decrease in IgM level (Table 3).
Thus, the results of clinical trials indicate the hepatoprotective properties of OVAGEN® and the
advisability of its use in the complex treatment of acute and chronic forms of liver damage in cancer
patients after radiation and chemotherapy as for the prevention of various liver diseases and their
complications.
During clinical trials of OVAGEN®, there were no side effects, contraindications, complications, or
drug dependence.
Influence of OVAGEN® on immunological parameters of patients with Table 3
chronic hepatitis
Parameters Before treatment After treatment with general After treatment using Ovagen®
purpose drugs
IgA, (g/l) 2,2±0,08 2,2±0,02 2,3±0,08
IgM, (g/l) 3,6±0,03 2,5±0,08* 2,1±0,03*
IgG, (g/l) 14,0±1,2 14,2±1,0 14,1±1,1
* P <0.05 - reliable in comparison with the parameter before treatment.
Для таблиц, дозировок и примечаний сверяйтесь с оригинальным PDF: при извлечении текста порядок колонок может измениться.
Из библиотеки Peptides. Авторство и содержание оригинала сохранены. Размещено с разрешения поставщика.